53611-47-5

Usage

Uses

Used in Pharmaceutical Industry:
2-Oxopiperidine-4-methano... is used as a key intermediate in the synthesis of cyclopropyl-amide, which acts as both LSD1 and HDAC6 inhibitors. These inhibitors are important in the development of new therapeutic agents targeting various diseases, including cancer and neurodegenerative disorders, by modulating specific enzyme activities and cellular pathways.
In the synthesis of cyclopropyl-amide, 2-Oxopiperidine-4-methano... contributes to the formation of the final product by providing a structural framework and functional groups that facilitate the formation of the desired amide bond and cyclopropyl moiety. This makes it a crucial component in the development of novel and effective drugs with potential applications in various therapeutic areas.

Upstream product

• 24537-50-6 (RS)-2-oxopiperidine-4-carboxylic acid 
• 25504-47-6 methyl (RS)-2-oxopiperidine-4-carboxylate 

Relevant academic research and scientific papers

NOVEL SELECTIVE CDK4/6 INHIBITOR AND PREPARATION THEREOF

The present disclosure discloses a compound as represented by formula (I) or a pharmaceutically acceptable salt, a solvate or an isomer thereof, a pharmaceutical composition and a pharmaceutical preparation comprising the same, and the application thereof in the field of medicine. As a selective inhibitor of cyclin-dependent kinase 4/6 (CDK4/6), the compound of the present disclosure may be used for treating or preventing a disease at least partially modulated by CDK4/6, such as breast cancer and colon cancer. [in-line-formulae]PBM-L-PDM?? (I)[/in-line-formulae]

METALLO-BETA-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF

The present invention relates to metallo-β-lactamase inhibitor compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein Z, RA, X1, X2 and R1 are as defined herein. The present invention also relates to compositions which comprise a metallo-β-lactamase inhibitor compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with a beta lactam antibiotic and/or a beta-lactamase inhibitor. The invention further relates to methods for treating a bacterial infection comprising administering to a patient a therapeutically effective amount of a compound of the invention, in combination with a therapeutically effective amount of one or more β-lactam antibiotics and optionally in combination with one or more beta-lactamase inhibitor compounds. The compounds of the invention are useful in the methods described herein for overcoming antibiotic resistance.